Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,459.70down ₹0.10 (0.00%)BSE ₹3,459.85
Share price at the NSE close on 29 Oct 2026. Previous close ₹3,459.80.
29 Oct: open ₹3,459.80, high ₹3,467.00, low ₹3,378.00
52-week range of traded prices to 29 Oct 2026
₹2,401.00Low, 29 Oct 2025₹3,796.00High, 18 Aug 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43,232 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.73%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 27.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 43,18348.7% delivered
Ajanta Pharma share news and announcements
810 announcements, routine notices left out, newest first. Page 3 of 17.
Apr 2025
30 Apr · Results
22 Apr · Analysts
22 Apr · Board meeting
Mar 2025
20 Mar · Business
Feb 2025
20 Feb · Analysts
7 Feb · Analysts
5 Feb · Updates
Jan 2025
30 Jan · General Updates
30 Jan · Board meeting
30 Jan · Results
17 Jan · Analysts
17 Jan · Board meeting
Dec 2024
Oct 2024
28 Oct · Corporate action
28 Oct · Results
23 Oct · Corporate action
17 Oct · Analysts
17 Oct · Board meeting
17 Oct · Updates
Sep 2024
18 Sep · Analysts
Aug 2024
8 Aug · Analysts
Jul 2024
30 Jul · Disclosure
30 Jul · Board meeting
30 Jul · Results
18 Jul · Meeting
17 Jul · Analysts
17 Jul · Board meeting
Meeting on 30 Jul 2024: “AJANTA PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Jul-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended”
Jun 2024
28 Jun · Closure of Buy Back
14 Jun · Updates
May 2024
13 May · Analysts